

Amendments to the Claims:

This listing of claims will replace all prior listings and versions of claims in this application.

1-10. (Cancelled)

11. (Currently Amended) An antibody which specifically binds to a polypeptide of SEQ ID NO:2120 according to claim 8, wherein the polypeptide is shown as Figure 5242 (SEQ ID NO:2120), wherein said antibody modulates activity of T cells.

12. (Previously presented) The antibody of claim 11, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

13. (Currently Amended) A composition of matter comprising ~~(a) a polypeptide of claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an~~ antibody of Claim 11 that binds to said polypeptide, in combination with a carrier, ~~wherein the polypeptide is shown as Figure 5242 (SEQ ID NO:2120).~~

14. (Previously presented) The composition of matter of claim 13, wherein said carrier is a pharmaceutically acceptable carrier.

15. (Currently amended) The composition of matter of claim 14 comprising a therapeutically effective amount of ~~(a), (b), (c) or (d)~~ the antibody of Claim 11.

16. (Currently Amended) An article of manufacture, comprising:

a container;

a label on said container; and

a composition of matter of Claim 15 ~~comprising (a) a polypeptide of claim 8, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide~~, contained within said container, ~~wherein the polypeptide is shown as Figure 5242 (SEQ ID NO:2120) and~~ wherein label on said container indicates that said composition of matter can be used for treating an immune related disease.

17-27. (Cancelled)